Table 1. .
Summary of head and neck cancer patients
| Age (years) |
Sex | Subsites | Histology | T-classification | Dose Gy (RBE) |
Number of fractions | Skin reaction Maximum/3 months |
Mucosal reaction Maximum/3 months |
|---|---|---|---|---|---|---|---|---|
| 66 | Female | Nasal cavity | Melanoma | T3 | 57.6 | 16 | Grade 1/0 | Grade 2/1 |
| 43 | Male | Maxillary Sinus | ACC | T4b | 64 | 16 | Grade 1/0 | Grade 2/0 |
| 69 | Male | Maxillary Sinus | ACC | T4a | 64 | 16 | Grade 1/0 | Grade 2/0 |
| 74 | Female | Maxillary sinus | ACC | T4b | 64 | 16 | Grade 1/0 | Grade 2/0 |
| 75 | Male | Oropharynx | PDC | T4a | 57.6 | 16 | Grade 0/0 | Grade 2/1 |
| 74 | Female | Ethmoid sinus | Melanoma | T3 | 57.6 | 16 | Grade 1/1 | Grade 1/0 |
| 74 | Male | Nasopharynx | Adenocarcinoma | T3 | 64 | 16 | Grade 0/0 | Grade 2/0 |
| 51 | Female | Parotid | Carcinoma | T4b | 64 | 16 | Grade 1/0 | Grade 0/0 |
ACC, adenoid cystic carcinoma; PDC, poorly differentiated carcinoma; RBE, relative biological effectiveness.